Sadikot Shaukat, Jothydev K, Zargar A H, Ahmad Jamal, Arvind S R, Saboo Banshi
International Diabetes Federation, Executive Board Member - International Atherosclerosis Association, Consultant at Jaslok Hospital and Research, Centre, Mumbai, India.
Department of Diabetology, Jyothydev's Diabetes and Research Centre (JDC), Trivandrum, India.
Diabetes Metab Syndr. 2017 Dec;11 Suppl 2:S811-S819. doi: 10.1016/j.dsx.2017.06.003. Epub 2017 Jun 13.
Diabetes management during Ramadan is very crucial from the patient perspective as it can present significant risk of hypoglycemia and death when proper care is not taken. Moreover, managing diabetes in fasting Ramadan patients require different mechanisms than the routine diabetes management and pose significant challenge to the health care practitioners. Here we set forth to review the available literature of various clinical trials and studies on different antidiabetic agents in the context of Ramadan. On the basis of available evidence, we suggest that gliclazide is effective and it could be safely recommended in type 2 diabetic patients fasting during Ramadan.
从患者角度来看，斋月期间的糖尿病管理至关重要，因为若不采取适当护理，可能会出现低血糖和死亡的重大风险。此外，在斋月禁食的糖尿病患者中管理糖尿病需要与常规糖尿病管理不同的机制，这给医护人员带来了重大挑战。在此，我们着手回顾斋月背景下关于不同抗糖尿病药物的各种临床试验和研究的现有文献。基于现有证据，我们建议格列齐特是有效的，并且可以安全地推荐给斋月期间禁食的2型糖尿病患者。
